1. "2024"
Formats
  1. Journal Article (2329)
  2. Meeting Abstract (1694)
  3. Review (589)
  4. Editorial (305)
  5. Book Section (98)
  6. Correspondence (92)
  7. Guidelines (90)
  8. Research Letter (89)
  9. Miscellaneous (55)
  10. Conference Paper (33)
  11. Book Whole (3)
Groups
  1. Department of Medicine (2141)
  2. Solid Tumor Oncology Division (1382)
  3. Sloan Kettering Institute Postdocs (1038)
  4. Surgery (984)
  5. Graduate Medical Education (883)
  6. GSK Faculty (868)

More Groups

People
  1. Eileen O'Reilly (75)
  2. Saad Usmani (75)
  3. Edward Christopher Dee (70)
  4. Nadeem Abu-Rustum (70)
  5. Alice Wei (69)
  6. T Peter Kingham (68)

More People

Years
  1. 2024 (5377)
Publications
  1. Journal of Clinical Oncology (521)
  2. International Journal of Radiation Oncology, Biology, Physics (186)
  3. Blood (161)
  4. Annals of Oncology (147)
  5. Annals of Surgical Oncology (131)
  6. Laboratory Investigation (91)

More Publications

Publishers
  1. Elsevier Inc. (784)
  2. American Society of Clinical Oncology (580)
  3. Nature Publishing Group (384)
  4. Springer (357)
  5. Oxford University Press (347)
  6. Elsevier Science, Inc. (256)

More Publishers

Results (5377)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mechanisms of resistance to selpercatinib in RET activated NSCLC and MTC from the LIBRETTO-001 trial
    Meeting Abstract

    Solomon, B. J.; Drilon, A. E.; Wirth, L. J.; Szpurka, A.; Rao, X.; Massey, A. C.; Barker, S.; Wright, J.; Won, H.; Cabanillas, M. E.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab
    Meeting Abstract

    Passaro, A.; Yu, H. A.; Nguyen, D.; Lee, V. H. F.; Soo, R. A.; Kim, S. H.; Daga, H.; Tan, D. S. W.; Kim, S. W.; Juan Vidal, O. J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours
    Meeting Abstract

    Drilon, A. E.; Lin, J. J.; Johnson, M. L.; Baik, C. S.; Paz-Ares, L. G.; Besse, B.; Mazieres, J.; Swalduz, A.; Minchom, A. R.; Reuss, J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours
    Meeting Abstract

    Besse, B.; Drilon, A. E.; Cho, B. C.; Camidge, D. R.; Neal, J.; Lin, C. C.; Liu, S. V.; Nagasaka, M.; Kao, S. C. H.; Felip, E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses
    Meeting Abstract

    Chan, J.; Geyer, S.; Zemla, T.; Knopp, M. V.; Behr, S. C.; Pulsipher, S.; Acoba, J.; Shergill, A.; Wolin, E. M.; Halfdanarson, T. R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant nivolumab and nivolumab+ipilimumab in resectable non-small cell lung cancer: Combined analysis of 5-year outcomes from NEOSTAR and CA209-159
    Meeting Abstract

    Reuss, J.; Leung, C. H.; Rosner, S.; Zhou, N.; Weissferdt, A.; Pataer, A.; Nassib William, W. Jr; Taube, J.; Broderick, S.; Spicer, J. D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Impact of multicancer early detection (MCED) test on participant-reported outcomes (PRO) and behavioral intentions by cancer risk
    Meeting Abstract

    Dilaveri, C. A.; McDonnell, C. H. 3rd; Klein, E. A.; Reid, R.; Marinac, C. R.; Nadauld, L.; Chung, K. C.; Lopatin, M.; Fung, E. T.; Schrag, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Modeled economic and clinical impact of a multi-cancer early detection (MCED) test in a population with hereditary cancer syndromes
    Meeting Abstract

    Raoof, S.; Tafazzoli, A.; Kansal, A.; Shaul, A.; Ye, W.; Fendrick, M.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • EGFR evaluation in non-small cell lung cancer: An artificial intelligence approach to pre-molecular analysis
    Meeting Abstract

    Vanderbilt, C. M.; Nanda, S.; Singi, S.; Gupta, R.; Goldgof, G.; Ardon, O.; Elkrief, A.; Fuchs, T.; Campanella, G.; Hameed, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma
    Meeting Abstract

    Betof Warner, A.; Smithy, J. W.; Los, C.; Kalvin, H.; Hasson, N.; Amaria, R. N.; Andrade Czapla, J. A.; Schollenberger, M.; furness, A.; Hassel, J. C.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save